Gerard  Brophy net worth and biography

Gerard Brophy Biography and Net Worth

EVP of Avantor
Dr. Ger Brophy is our Executive Vice President, Biopharma Production. In his current role, Dr. Brophy is responsible for developing and implementing our Biopharma Production offering to support the current and future needs of our customers. Prior to joining Avantor, Dr. Brophy held a variety of research and development, strategy, advanced systems, and business development positions with GE Healthcare Life Sciences, GE Healthcare Medical Diagnostics and Amersham for nearly 30 years. Dr. Brophy earned a Bachelor of Science in biotechnology, as well as a doctorate in molecular biology from Dublin City University in Ireland.

What is Gerard Brophy's net worth?

The estimated net worth of Gerard Brophy is at least $2.31 million as of March 3rd, 2023. Dr. Brophy owns 108,715 shares of Avantor stock worth more than $2,305,845 as of December 22nd. This net worth estimate does not reflect any other investments that Dr. Brophy may own. Learn More about Gerard Brophy's net worth.

How do I contact Gerard Brophy?

The corporate mailing address for Dr. Brophy and other Avantor executives is BUILDING ONE SUITE 200 100 MATSONFORD ROAD, RADNOR PA, 19087. Avantor can also be reached via phone at (610) 386-1700 and via email at [email protected]. Learn More on Gerard Brophy's contact information.

Has Gerard Brophy been buying or selling shares of Avantor?

Gerard Brophy has not been actively trading shares of Avantor during the last ninety days. Most recently, Gerard Brophy sold 3,914 shares of the business's stock in a transaction on Friday, March 3rd. The shares were sold at an average price of $25.00, for a transaction totalling $97,850.00. Following the completion of the sale, the executive vice president now directly owns 108,715 shares of the company's stock, valued at $2,717,875. Learn More on Gerard Brophy's trading history.

Who are Avantor's active insiders?

Avantor's insider roster includes James Bramwell (EVP), Gerard Brophy (EVP), Christophe Couturier (EVP), Steven Eck (CAO), Rajiv Gupta (Director), Justin Miller (EVP), Jo Natauri (Director), Devashish Ohri (EVP), Christi Shaw (Director), Michael Stubblefield (President, CEO & Director), Thomas Szlosek (CFO), Frederic Vanderhaegen (EVP), and Michael Wondrasch (EVP). Learn More on Avantor's active insiders.

Are insiders buying or selling shares of Avantor?

In the last twelve months, insiders at the sold shares 2 times. They sold a total of 9,728 shares worth more than $240,247.97. The most recent insider tranaction occured on September, 5th when CAO Steven W Eck sold 3,525 shares worth more than $88,336.50. Insiders at Avantor own 1.5% of the company. Learn More about insider trades at Avantor.

Information on this page was last updated on 9/5/2024.

Gerard Brophy Insider Trading History at Avantor

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/3/2023Sell3,914$25.00$97,850.00108,715View SEC Filing Icon  
2/2/2023Sell11,339$25.06$284,155.34102,385View SEC Filing Icon  
5/20/2022Sell19,603$31.27$612,985.8196,935View SEC Filing Icon  
3/1/2022Sell2,027$34.47$69,870.69View SEC Filing Icon  
2/23/2022Sell3,059$33.79$103,363.61View SEC Filing Icon  
1/5/2022Sell11,551$38.65$446,446.15View SEC Filing Icon  
1/3/2022Sell59,418$40.77$2,422,471.86View SEC Filing Icon  
7/30/2021Sell81,125$37.24$3,021,095.00View SEC Filing Icon  
2/24/2021Sell3,059$27.93$85,437.87172,384View SEC Filing Icon  
2/22/2021Sell19,769$28.62$565,788.78175,443View SEC Filing Icon  
1/6/2021Sell11,509$27.24$313,505.16178,515View SEC Filing Icon  
1/4/2021Sell59,418$27.84$1,654,197.12190,024View SEC Filing Icon  
5/20/2020Sell25,495$17.36$442,593.20196,583View SEC Filing Icon  
See Full Table

Gerard Brophy Buying and Selling Activity at Avantor

This chart shows Gerard Brophy's buying and selling at Avantor by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Avantor Company Overview

Avantor logo
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, and compound management services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Read More

Today's Range

Now: $21.21
Low: $20.95
High: $21.47

50 Day Range

MA: $22.15
Low: $19.72
High: $25.06

2 Week Range

Now: $21.21
Low: $19.59
High: $28.00

Volume

10,967,709 shs

Average Volume

6,461,251 shs

Market Capitalization

$14.44 billion

P/E Ratio

46.11

Dividend Yield

N/A

Beta

1.29